LEPU BIO (02157) announced its interim results, with net profit attributable to shareholders of 27.393 million yuan, a year-on-year decrease of 34.4%.

LEPU BIO (02157) reported its performance for the six months ending June 30, 2026, with revenue of 522 million yuan, a year-on-year increase of 12.1%; profit attributable to shareholders was 27.393 million yuan, a year-on-year decrease of 34.4%; basic earnings per share were 0.02 yuan. During the period, revenue grew steadily. In terms of domestic commercialization, the group achieved sales revenue of approximately 371.3 million yuan from Meiyouheng (Injection of Vebecotamab) and Puyouheng (Injection of Putilizumab), more than double the sales revenue for the same period in 2025 (for the six months ending June 30, 2025: 150.6 million yuan). Regarding licensing operations, the group recorded revenue of approximately 148.7 million yuan from subsequent milestone payments, primarily due to licensing deals for CMG901 and MRG007. As of now, the company has successfully commercialized two drugs in the Chinese domestic market, and multiple candidate drugs have entered critical clinical stages, advancing treatment lines through combination therapy. Meanwhile, the company continues to promote new drug research and development based on its own innovative technology platform and explores new business development cooperation opportunities.